Nordea Investment Management AB Has $3.26 Million Stake in DexCom, Inc. $DXCM

Nordea Investment Management AB decreased its position in DexCom, Inc. (NASDAQ:DXCM) by 51.3% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 37,683 shares of the medical device company’s stock after selling 39,733 shares during the period. Nordea Investment Management AB’s holdings in DexCom were worth $3,264,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Nvest Financial LLC acquired a new position in DexCom in the second quarter valued at $225,000. Bridges Investment Management Inc. acquired a new position in DexCom in the second quarter valued at $256,000. Patten & Patten Inc. TN lifted its holdings in DexCom by 6.1% in the second quarter. Patten & Patten Inc. TN now owns 82,738 shares of the medical device company’s stock valued at $7,222,000 after buying an additional 4,780 shares during the period. Generali Asset Management SPA SGR lifted its holdings in DexCom by 9.4% in the second quarter. Generali Asset Management SPA SGR now owns 18,545 shares of the medical device company’s stock valued at $1,619,000 after buying an additional 1,591 shares during the period. Finally, Curated Wealth Partners LLC acquired a new position in shares of DexCom during the second quarter valued at about $359,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Performance

DexCom stock opened at $69.75 on Wednesday. The firm’s fifty day moving average price is $72.95 and its 200-day moving average price is $77.70. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The stock has a market cap of $27.35 billion, a P/E ratio of 48.44, a price-to-earnings-growth ratio of 1.44 and a beta of 1.47. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business’s quarterly revenue was up 15.2% on a year-over-year basis. During the same quarter last year, the company posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. On average, equities research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Activity at DexCom

In other news, EVP Michael Jon Brown sold 500 shares of the firm’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $80.29, for a total transaction of $40,145.00. Following the sale, the executive vice president owned 94,102 shares in the company, valued at approximately $7,555,449.58. This trade represents a 0.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction on Friday, August 15th. The shares were sold at an average price of $81.06, for a total transaction of $222,915.00. Following the transaction, the director directly owned 51,121 shares in the company, valued at approximately $4,143,868.26. This represents a 5.10% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,849 shares of company stock worth $564,733. Corporate insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the topic of several research reports. Raymond James Financial upped their price objective on shares of DexCom from $99.00 to $102.00 and gave the company a “strong-buy” rating in a report on Thursday, July 31st. Oppenheimer lowered shares of DexCom from an “outperform” rating to a “market perform” rating in a report on Monday, September 8th. Morgan Stanley upped their price objective on shares of DexCom from $82.00 to $89.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. Truist Financial decreased their price objective on shares of DexCom from $102.00 to $94.00 and set a “buy” rating for the company in a research note on Wednesday, October 15th. Finally, Robert W. Baird reduced their target price on shares of DexCom from $112.00 to $90.00 and set an “outperform” rating for the company in a research report on Friday, September 26th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $96.40.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.